Great companies attract great talent.
None more so than IXICO , a £10m marketcap, AI powered medical imaging analytics firm, which is materially outperforming the broader CRO sector.
Today the company announced that it had appointed two prominent global Alzheimer's Disease and vascular experts to its Scientific Advisory Board. Namely Professor Micheal Weiner (MD), who is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry and Neurology at the University of California, San Francisco. Alongside Professor Joanna Wardlaw (MD, CBE), who similarly is a Professor of Applied Neuroimaging at the University of Edinburgh and Consultant Neuroradiologist for NHS Lothian.
These appointments support IXICO's strategy to deepen its presence in Alzheimer's Disease and develop a series of biomarker algorithms to identify and measure vascular abnormalities. Which are a common contributing factor in neurodegenerative disease, where MRI can provide an established biomarker for vascular abnormalities.
Chief Scientific Officer Robin Wolz commenting: "Collaborating with distinguished experts in the field directly supports our work to develop and validate vascular biomarker algorithms that address a critical gap in current AD trials.”
Finally wrt the numbers, house broker Cavendish are forecasting FY26 EBITDA of -£1.6m on turnover of £6.9m (+9.5% vs £6.3m LY), augmented by a 24p/share price target. Net cash closed Sept’25 at £3.5m. FY25 results are due out on Tuesday 9th December.
Disclosure: IXICO is a Vox Markets client.